CADL earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -10.26. Updated 2026-07-23.
Candel Therapeutics (CADL) Research Hub
Candel Therapeutics (CADL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 10.545 USD (-13.35%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.26, market cap 0.55B. This hub links to the full technical, earnings and options research available for CADL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 10.545 USD (-13.35%) |
| 52-week range | 7.95 USD – 13.95 USD |
| Trend regime | Range |
| 14-day RSI | 49.7 (Neutral) |
| Trailing P/E | -10.26 |
| Market cap | 0.55B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for CADL
Covered Call on CADL: how it works, illustrative setup around the real 10.54 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CADL: how it works, illustrative setup around the real 10.54 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CADL: how it works, illustrative setup around the real 10.54 USD price, max profit/loss, breakeven and when to use it. Educational.
CADL technical analysis: range, last 10.545 USD, RSI 49.7, 52w range 7.95 USD–13.95 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CADL in?
Candel Therapeutics (CADL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CADL in an uptrend or downtrend?
As of 2026-09-11, CADL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CADL's trailing P/E ratio?
CADL's trailing P/E is -10.26, with a market cap of 0.55B. See the earnings research page for full valuation detail.
When does CADL next report earnings?
CADL is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.22 USD.